The success of target validation and lead optimization largely depends on how closely a biological model mimics the complexities of human diseases. Discrepancies between experimental settings and clinical pathology often lead to attrition in the late stages of drug development.

In this webinar, Melanie Homberg and Kevin Grady will discuss strategies for integrating high-throughput CRISPR screens and advanced biological models to accelerate drug discovery workflows.

Topics to discuss:

• Criteria for selecting disease-relevant models to improve target validation.
• High-throughput CRISPR screening methods to identify novel targets
• Advanced in vitro and live Models to improve translational success.
• Practical approaches to align model selection with fabric and safety requirements.

Wednesday, April 22, 2026 | 11:00 am to 12:00 pm Eastern Time
This webinar will be available to view live and on-demand.

Speakers

Melanie Homberg, PhD
Market Development Manager
Lonza

Kevin Grady
Associate Director, Market Strategy
Lonza